HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

WL 276

a Bcl-2 antagonist and antineoplastic agent; structure in first source

Also Known As:

WL-276; WL276 cpd

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - WL 276: 1
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - WL 276: 1
  - Thiazoles: 392
    - WL 276: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - WL 276: 1

Experts

1.	Addo, Sadiya N: 1 article (06/2008)
2.	Slaton, Joel W: 1 article (06/2008)
3.	Sloper, Daniel T: 1 article (06/2008)
4.	Tian, Defeng: 1 article (06/2008)
5.	Wang, Liangyou: 1 article (06/2008)
6.	Xing, Chengguo: 1 article (06/2008)

Related Diseases

1.

Neoplasms (Cancer)

06/01/2008 - "The selective toxicity of WL-276 against drug-resistant PC-3 cells and its in vivo suppression of PC-3 prostate tumor growth suggest that WL-276 is a promising lead candidate for the development of Bcl-2 antagonists against drug-resistant HRPC."
06/01/2008 - "The anticancer activity of WL-276 was manifested in its suppression of PC-3-induced prostate tumor growth in vivo. "
06/01/2008 - "In addition, three PC-3 cell lines with acquired drug resistance against standard cancer chemotherapies were more sensitive to WL-276 than the parent PC-3 cell line. "
06/01/2008 - "WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth."

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)